9YEL | pdb_00009yel

Human muscle nAChR SCCMS eL269F ACh, Fluoxetine bound

  • Classification: MEMBRANE PROTEIN
  • Organism(s): Homo sapiens
  • Expression System: Homo sapiens
  • Mutation(s): Yes 

  • Deposited: 2025-09-24 Released: 2026-08-05 
  • Deposition Author(s): Li, H., Hibbs, R.E.
  • Funding Organization(s): National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS)

Experimental Data Snapshot

  • Method: ELECTRON MICROSCOPY
  • Resolution: 2.48 Å
  • Aggregation State: PARTICLE 
  • Reconstruction Method: SINGLE PARTICLE 

wwPDB Validation 3D Report Full Report

Validation slider image for 9YEL

This is version 1.0 of the entry. See complete history

Literature

Correcting congenital myasthenia-associated acetylcholine receptor defects.

Li, H.Mukhtasimova, N.Teng, J.Cavalli, E.S.Gu, X.Sello, J.K.Sine, S.M.Hibbs, R.E.

(2026) Nature 

  • DOI: https://doi.org/10.1038/s41586-026-10706-1
  • Primary Citation Related Structures: 
    9YE6, 9YE7, 9YE8, 9YEH, 9YEI, 9YEK, 9YEL, 9YER, 9YET, 9YEU, 9YEX, 9YF0

  • PubMed Abstract: 

    Voluntary muscle contraction is triggered by the neurotransmitter acetylcholine binding its receptors on the postsynaptic membrane of the neuromuscular junction, opening ion channels that allow cation influx and initiate depolarization 1-3 . Mutations in muscle acetylcholine receptors disrupt this process by either impairing (fast-channel) or prolonging (slow-channel) channel openings 1,4 . These defects cause congenital myasthenic syndromes (CMS), characterized by severe muscle weakness that is often present at birth and, in some cases, progresses to paralysis and death 5,6 . The structural mechanisms underlying these pathogenic defects and their pharmacological correction remain unknown. Here, using cryogenic electron microscopy, chemical biology and electrophysiology, we determined the structures and functional consequences of representative CMS mutant receptors with and without drugs. In fast-channel disease-associated mutants, we discovered a cryptic allosteric site targeted by positive modulators that restore gating in a mutation-specific manner. In receptor mutants associated with slow-channel disease, quinidine, fluoxetine and reboxetine act as pore blockers; notably, the antidepressant reboxetine selectively blocks desensitized receptors in a mutation-independent fashion, suggesting repurposing potential. Mechanistically, fast-channel mutations uncouple agonist binding from gating, whereas slow-channel mutations stabilize an abnormally widened, desensitized-like pore. These findings reveal unifying principles of CMS pathogenesis and provide a framework for precision therapies.


  • Organizational Affiliation
    • Department of Neurobiology, University of California, San Diego, La Jolla, CA, USA.

Macromolecule Content 

  • Total Structure Weight: 268.8 kDa 
  • Atom Count: 16,737 
  • Modeled Residue Count: 2,042 
  • Deposited Residue Count: 2,323 
  • Unique protein chains: 4

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
Acetylcholine receptor subunit alphaA,
B [auth C]
437Homo sapiensMutation(s): 0 
Gene Names: CHRNA1ACHRACHNRA
UniProt & NIH Common Fund Data Resources
Find proteins for P02708 (Homo sapiens)
Explore P02708 
Go to UniProtKB:  P02708
PHAROS:  P02708
GTEx:  ENSG00000138435 
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP02708
Glycosylation
Glycosylation Sites: 1Go to GlyGen: P02708-2
Sequence Annotations
Expand
Reference Sequence
Find similar proteins by:|  3D Structure
Entity ID: 2
MoleculeChains  Sequence LengthOrganismDetailsImage
Acetylcholine receptor subunit betaC [auth E]480Homo sapiensMutation(s): 0 
Gene Names: CHRNB1ACHRBCHRNB
UniProt & NIH Common Fund Data Resources
Find proteins for P11230 (Homo sapiens)
Explore P11230 
Go to UniProtKB:  P11230
PHAROS:  P11230
GTEx:  ENSG00000170175 
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP11230
Glycosylation
Glycosylation Sites: 1Go to GlyGen: P11230-1
Sequence Annotations
Expand
Reference Sequence
Find similar proteins by:|  3D Structure
Entity ID: 3
MoleculeChains  Sequence LengthOrganismDetailsImage
Acetylcholine receptor subunit delta496Homo sapiensMutation(s): 0 
Gene Names: CHRNDACHRD
UniProt & NIH Common Fund Data Resources
Find proteins for Q07001 (Homo sapiens)
Explore Q07001 
Go to UniProtKB:  Q07001
PHAROS:  Q07001
GTEx:  ENSG00000135902 
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ07001
Glycosylation
Glycosylation Sites: 1Go to GlyGen: Q07001-1
Sequence Annotations
Expand
Reference Sequence
Find similar proteins by:|  3D Structure
Entity ID: 4
MoleculeChains  Sequence LengthOrganismDetailsImage
Acetylcholine receptor subunit epsilonE [auth B]473Homo sapiensMutation(s): 1 
Gene Names: CHRNEACHRE
UniProt & NIH Common Fund Data Resources
Find proteins for Q04844 (Homo sapiens)
Explore Q04844 
Go to UniProtKB:  Q04844
PHAROS:  Q04844
GTEx:  ENSG00000108556 
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ04844
Glycosylation
Glycosylation Sites: 2Go to GlyGen: Q04844-1
Sequence Annotations
Expand
Reference Sequence

Oligosaccharides

Help  
Entity ID: 5
MoleculeChains Length2D Diagram GlycosylationD Interactions
alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
F, G, I
5N-Glycosylation
Entity ID: 6
MoleculeChains Length2D Diagram GlycosylationD Interactions
beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
H, J
3N-Glycosylation

Experimental Data & Validation

Experimental Data

  • Method: ELECTRON MICROSCOPY
  • Resolution: 2.48 Å
  • Aggregation State: PARTICLE 
  • Reconstruction Method: SINGLE PARTICLE 
EM Software:
TaskSoftware PackageVersion
RECONSTRUCTIONcryoSPARC

Structure Validation

View Full Validation Report



Entry History 

& Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS)United States--

Revision History  (Full details and data files)

  • Version 1.0: 2026-08-05
    Type: Initial release